Recombinant Human VEGF165 Protein

ELISA: Immobilized Recombinant Human VEGF165 (Cat#orb2995236) at 2μg/ml (100 μl/well) can bind Human VEGF-A Antibody (Bevacizumab) (Human IgG1) (Cat#orb2992936) . The ED50 of Human VEGF-A Antibody (Bevacizumab) (Human IgG1) (Cat#orb2992936) is 2.20 ng/ml. (Regularly tested) Immobilized Human VEGF165 (Cat#orb2995236) at 10μg/ml (100 μl/well) can bind Human VEGFR1-Fc (Cat#orb2994454) . The ED50 of Recombinant Human VEGFR1-Fc (Cat#orb2994454) is 36.4 ng/ml. (Regularly tested) . BLI: Loaded Brolucizumab on AMC Biosensor, can bind Recombinant Human VEGF165 (Cat#orb2995236) with an affinity constant of 22.2 pM as determined in BLI assay. (Regularly tested) Loaded Human VEGF-A Antibody (Bevacizumab) (Cat#orb2992936) on Pro-A Biosensor, can bind Recombinant Human VEGF165 (Cat#orb2995236) with an affinity constant of 7.12 pM as determined in BLI assay. (Regularly tested) Loaded Human VEGFR1-Fc (Cat#orb2994454) on Protein A Biosensor, can bind Human VEGF165 (Cat#orb2995236) with an affinity constant of 0.29 nM as determined in BLI assay. (Regularly tested) . Cell Based Assay: Measured by its ability to induce calcineurin- NFAT signaling in 293-VEGF Res cells (Cat#Xorb3002411) . The ED50 for this effect is 1.56 ng/mL. (Regularly tested)

Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.